WHO Drug Information Vol. 15, No. 2, 2001
(2001; 91 pages) View the PDF document
Table of Contents
Open this folder and view contentsPersonal Perspectives
Open this folder and view contentsReports on Individual Drugs
Open this folder and view contentsVaccines and Biomedicines
Open this folder and view contentsCurrent Topics
Open this folder and view contentsGeneral Information
Open this folder and view contentsRegulatory and Safety Matters
Close this folderATC/DDD Classification
View the documentATC/DDD Classification (final)
View the documentATC/DDD Classification (temporary)
Open this folder and view contentsEssential Drugs
Open this folder and view contentsRecent Publications and Sources of Information
View the documentInternational Nonproprietary Names for Pharmaceutical Substances (INN)
View the documentDénominations communes internationales des Substances pharmaceutiques (DCI)
View the documentDenominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)
View the documentAmendments to previous lists/Modifications apportées aux listes antérieures/Modificaciones a las listas anteriores
View the documentAnnexes
 

ATC/DDD Classification (temporary)

The following temporary anatomical therapeutic chemical (ATC) classifications and defined daily doses (DDDs) were agreed at a meeting of the WHO International Working Group for Drug Statistics Methodology which took place on 4 - 6 June 2001. forwarded to the WHO Collaborating Centre for Drug Statistics Methodology, e-mail: whocc@nmd.no. If no objections are received, the new ATC codes and DDDs will be considered final and will be included in the January 2002 issue of the ATC index. The inclusion of a substance in the lists does not imply any recommendation of use in medicine or pharmacy.

ATC level

INN/common name

ATC code

     

New ATC level codes (other than 5th level):

   
 

Agents used in photodynamic therapy

 

L01XD

 

Bone morphogenetic proteins

 

M05BC

     

New ATC 5th level codes:

   
 

acetyldigoxin combination

C01AA52

 

agalsidase alfa

A16AB03

 

agalsidase beta

A16AB04

 

amlexanox

A01AD07

 

anakinra

L04AA14

 

arsenic trioxide

L01XX27

 

ascorbic acid

G01AD03

 

ascorbic acid

S01XA15

 

bisoxatin

A06AB09

 

BMP-2

M05BC01

 

BMP-7

M05BC02

 

cilnidipine

C08CA14

 

crilanomer

D03AX09

 

darbepoetin alfa

B03XA02

 

denileukin diftitox

L01XX29

 

dienogest and estrogen

G03FA15

 

diflucortolone

D07XC04

 

dimethyl sulfoxide

G04BX13

 

drotrecogin alfa

B01AD10

 

esomeprazole, amoxicillin

 
 

and clarithromycin

A02BD06

 

fomepizole

V03AB34

 

fondaparinux sodium

B01AB12

 

formoterol and other drugs

 
 

for obstructive airway diseases

R03AK07

 

fulvestrant

L02BA03

 

gadobutrol

V08CA09

 

hemoglobin raffimer

B05AA09

 

imatinib

L01XX28

 

insulin glargine

A10AE04

 

levocetirizine

R06AE08

 

lutropin alfa

G03GA07

 

methyl aminolevulinate

L01XD03

 

monobenzone

D11AX13

 

multienzymes and acid preparations

A09AC02

 

omalizumab

R03DX05

 

phloroglucinol

A03AX12

 

rupatadine

R06AX28

 

sodium selenite

A12CE02

 

sodium tartrate

A06AD21

 

tacrolimus

D11AX14

 

talinolol

C07AB13

 

tegafur, combinations

L01BC53

 

thioacetazone, combinations

J04AM04

 

tiotropium bromide

R03BB04

 

trimegestone and estrogen

G03FB11

 

unoprostone

S01EX04

 

vaginal ring with progestogen

 
 

and estrogen

G02BB01

 

zinc acetate

A16AX05

     

ATC code changes

   
 

Previous:

porfimer sodium

L01XX15

 

New:

porfimer sodium

L01XD01

 

Previous:

verteporfin

L01XX26

 

New:

verteporfin

L01XD02

 

Previous:

alginic acid

A02EA01

 

New:

alginic acid

A02BX13

 

Previous:

silicones

A02DA01

 

New:

silicones

A03AX13

     

ATC name changes

   
 

Previous: Drugs affecting mineralization

 
 

New: Drugs affecting bone structure and mineralization

M05B

 

Previous: Anti-asthmatics

 
 

New: Drugs for obstructive airway diseases

R03

 

Previous: Adrenergics and other anti-asthmatics

 
 

New: Adrenergics and other drugs for obstructive airway diseases

R03AK

 

Previous: Epinephrine and other anti-asthmatics

 
 

New: Epinephrine and other drugs for obstructive airway diseases

R03AK01

 

Previous: Isoprenline and other anti-asthmatics

 
 

New: Isoprenaline and other drugs for obstructive airway diseases

R01AK02

 

Previous: Fenoterol and other anti-asthmatics

 
 

New: Fenoterol and other drugs for obstructive airway diseases

R01AK03

 

Previous: Antacids, drugs for treatment of peptic ulcer and flatulence

 
 

New: Drugs for acid related disorders

A02

 

Previous: Drugs for treatment of peptic ulcer

 
 

New: Drugs for peptic ulcer and gastroesophageal reflux disease (GERD)

A02B

 

Previous: Other drugs for treatment of peptic ulcer

 
 

New: Other drugs for peptic ulcer and gastroesophageal reflux disease (GERD)

A02BX

     

ATC name changes

   
 

Previous: Antispasmodic and anticholinergic agents and propulsives

 
 

New: Drugs for functional gastrointestinal disorders

A03

 

Previous: Synthetic antispasmodic and anticholinergic agents

 
 

New: Drugs for functional bowel disorders

A03A

 

Previous: Other synthetic anticholinergic agents

 
 

New: Other drugs for functional bowel disorders

A03AK

 

Previous: Salbutamol and other anti-asthmatics

 
 

New: Salbutamol and other drugs for obstructive airway diseases

R03AK04

 

Previous: Reproterol and other anti-asthmatics

 
 

New: Reproterol and other drugs for obstructive airway diseases

R03AK05

 

Previous: Salmeterol and other anti-asthmatics

 
 

New: Salmeterol and other drugs for obstructive airway diseases

R03AK06

 

Previous: Other anti-asthmatics, inhalants

 
 

New: Other drugs for obstructive airway diseases, inhalants

R03B

 

Previous: Other anti-asthmatics, inhalants

 
 

New: Other drugs for obstructive airway diseases, inhalants

R03BX

 

Previous: Adrenergics and other anti-asthmatics

 
 

New: Adrenergics and other drugs for obstructive airway diseases

R03CK

 

Previous: Other anti-asthmatics for systemic use

 
 

New: Other systemic drugs for obstructive airway diseases

R03D

 

Previous: Other anti-asthmatics for systemic use

 
 

New: Other systemic drugs for obstructive airway diseases

R03DX

New DDDs:

INN/common name

DDD

Unit

Route of Administration

ATC code

almotriptan

12.5

mg

O

N02CC05

buprenorphine

8

mg

O

N07BC01

cilnidipine

10

mg

O

C08CA14

darbepoetin alfa*

4.5

mcg

P

B03XA02

desloratadine

5

mg

O

R06AX27

itraconazole

0.2

g

P

J02AC02

levocetirizine*

5

mg

O

R06AE08

mifepristone

0.6

g

O

G03XB01

mycofenolic acid

2

g

P

L04AA06

nimesulide

0.2

g

O

M01AX17

peginterferon alfa-2b

7.5

mcg

P

L03AB10

propacetamol

6

g

P

N02BE05

talinolol*

0.1

g

O

C07AB13

tobramycin

0.3

g

Inhal. sol.

J01GB01

zinc acetate*

0.15

g

O

A16AX05

         

DDD changes:

       
 

Previous: erythropoietin

2

TU

P

 
 

New: erythropoietin

1

TU

P

B03XA01

 

Previous: risedronic acid

30

mg

O

 
 

New: risedronic acid

5

mg

O

M05BA07

* Temporary ATC code

 

to previous section to next section
 

Last updated: May 3, 2013